Shanghai Jiatan Pharmaceutical Technology

Jiatan Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule targeted therapies for cancer. The company's pipeline focuses on high-impact oncogenic drivers, featuring its lead candidate JTN001, a highly selective CDK4/6 inhibitor currently being evaluated for breast cancer and other solid tumors. Additionally, Jiatan is advancing JTN002, a KRAS G12C inhibitor, and JTN003, a SHP2 inhibitor, into clinical development to address unmet needs in precision oncology. By leveraging its internal R&D capabilities and strategic collaborations, Jiatan aims to provide more effective and safer treatment options for cancer patients globally. The leadership team brings extensive experience from multinational pharmaceutical companies, positioning Jiatan as a rising player in the Chinese biotech ecosystem.